
In-Situ Gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic RhinosinusitisAward last edited on: 1/7/2020
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$579,745Award Phase
2Solicitation Topic Code
-----Principal Investigator
Bo LiangCompany Information
Phase I
Contract Number: 1R43AI138660-01Start Date: 4/1/2018 Completed: 3/31/2020
Phase I year
2018Phase I Amount
$279,745Public Health Relevance Statement:
Narrative Development of a long-acting in-situ gel nasal spray containing povidone iodine in combination with budesonide for the treatment of chronic rhinosinusitis, represents a major advance in rhinology. If approved, this will be the first broad-spectrum anti-infectious drug/steroid combination against all causes of pathogens with no drug resistance, long duration in the nasal cavity with better patient compliance and minimized irritation profile.
Project Terms:
absorption; Adult; Adverse effects; Affect; animal efficacy; Animals; Anti-Bacterial Agents; Antifungal Agents; Applications Grants; Area; Bacteria; Bacterial Model; Budesonide; Calcium ion; Candida albicans; Canis familiaris; Characteristics; Child; Chronic; Chronic Disease; chronic rhinosinusitis; Clinical; commercialization; Compliance behavior; Cystic Fibrosis; Delayed-Action Preparations; Dermatology; Development; Disease; Drug Delivery Systems; drug development; Drug resistance; efficacy study; Equilibrium; Formulation; functional disability; fungus; Gel; Goals; Histopathologic Grade; Hour; Human; In Situ; In Vitro; in vivo; Infection; Inflammatory; Ions; Irrigation; irritation; Lead; Licensing; Local Anti-Infective Agents; Medical; Microbial Biofilms; Modeling; Mucositis; Mucous body substance; Multi-Drug Resistance; Nasal cavity; Nasal Polyps; New Zealand; Nose; novel; Operative Surgical Procedures; ophthalmic drug; Ophthalmology; Oryctolagus cuniculus; Otolaryngology; pathogen; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Phase; Phase II Clinical Trials; Phase Transition; physical symptom; Physicians; Polysaccharides; potassium ion; Povidone-Iodine; Process; Property; Pseudomonas aeruginosa; Rattus; Recurrence; residence; Resistance; rhinosinusitis; Rodent; Role; Safety; Saline; Secondary to; Sedimentation process; Sheep; Sinus; Sinusitis; Site; Small Business Innovation Research Grant; sodium ion; Staphylococcus aureus; Steroids; Structure of mucous membrane of nose; Study models; Surface; Suspensions; Symptoms; Technology; Testing; Therapeutic; Time; Tissues; Toxic effect; Toxicology; treatment duration; uptake; Viscosity
Phase II
Contract Number: 5R43AI138660-02Start Date: 4/1/2018 Completed: 3/31/2020
Phase II year
2019Phase II Amount
$300,000Public Health Relevance Statement:
Narrative Development of a long-acting in-situ gel nasal spray containing povidone iodine in combination with budesonide for the treatment of chronic rhinosinusitis, represents a major advance in rhinology. If approved, this will be the first broad-spectrum anti-infectious drug/steroid combination against all causes of pathogens with no drug resistance, long duration in the nasal cavity with better patient compliance and minimized irritation profile.
NIH Spending Category:
Biodefense; Biotechnology; Emerging Infectious Diseases; Infectious Diseases
Project Terms:
absorption; Adult; Adverse effects; Affect; animal efficacy; Animals; Anti-Bacterial Agents; Antifungal Agents; Applications Grants; Area; Bacteria; Bacterial Model; Budesonide; Calcium ion; Candida albicans; Canis familiaris; Characteristics; Child; Chronic; Chronic Disease; chronic rhinosinusitis; Clinical; commercialization; compliance behavior; Cystic Fibrosis; Delayed-Action Preparations; Dermatology; Development; Disease; Drug Delivery Systems; drug development; Drug resistance; efficacy study; Equilibrium; Formulation; functional disability; fungus; Gel; Goals; Histopathologic Grade; Hour; Human; In Situ; In Vitro; in vivo; Infection; Inflammatory; Ions; Irrigation; irritation; Lead; Licensing; Local Anti-Infective Agents; Medical; Microbial Biofilms; Modeling; Mucositis; Mucous body substance; Multi-Drug Resistance; Nasal cavity; Nasal Polyps; New Zealand; Nose; novel; Operative Surgical Procedures; ophthalmic drug; Ophthalmology; Oryctolagus cuniculus; Otolaryngology; pathogen; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Phase; Phase II Clinical Trials; Phase Transition; physical symptom; Physicians; Polysaccharides; potassium ion; Povidone-Iodine; Process; Property; Pseudomonas aeruginosa; Rattus; Recurrence; residence; Resistance; rhinosinusitis; Rodent; Role; Safety; Saline; Secondary to; Sedimentation process; Sheep; Sinus; Sinusitis; Site; Small Business Innovation Research Grant; sodium ion; Staphylococcus aureus; Steroids; Structure of mucous membrane of nose; Study models; Surface; Suspensions; Symptoms; Technology; Testing; Therapeutic; Time; Tissues; Toxic effect; Toxicology; treatment duration; uptake; Viscosity